Focal ablation uses precisely targeted energy delivered through a small insertion and guided towards its target. However one of the challenges is that there is an unpredictable amount of tissue as the damage radiates out. The reason for significant interest in focal therapies is that that they offer the possibility of treating only the cancer areas so minimizing the potential morbidity.

Almost all ablative technologies are radial (or centre to periphery, i.e. where tissue destruction starts from the centre of a probe or seed and spreads outwards to the periphery).

Most developers focus on new ablative technologies which reduce the magnitude of the problem instead of solving its radial nature. Trod Medical has developed a novel approach to the challenges that ablative technologies face.

Trod Medical's first product approved is the Encage™ an innovative application of a well-established technology that enables the user to destroy tissue in a highly controlled manner.

The Encage™ uses a confined, radiofrequency based, bipolar, helical ablation probe. The use of a coiled field to deliver uniform tissue destruction within that area minimising collateral damage. The helical bipolar design produces an electrical field which concentrates and confines the destruction within the "cage" limits, thereby completely avoiding the radial effect that is often seen with other technologies this innovative approach uses concentric coiled needles. This maximises the safety margin (so that even if the loading current is exceeded, there is no overheating and no collateral tissue is damage)

The site specific accuracy is also maximised as the active end of the device can be visualised before and during ablation using synched ultrasound imaging.

Further work is ongoing to refine links with MRI technology which allows for multiple modalities to be used to maximise accuracy of imaging and alignment of ablation.

Encage™ is currently been used in prostate focal therapy.